Literature DB >> 23222280

Expression of girdin in human colorectal cancer and its association with tumor progression.

Byoung Yeon Jun1, Sang Woo Kim, Chan Kwon Jung, Yu Kyung Cho, In Seok Lee, Myung-Gyu Choi, Kyu Yong Choi, Seong Taek Oh.   

Abstract

BACKGROUND: Girdin is crucial for cellular motility in cancer cell lines and for metastasis in a mouse model. Its expression has been demonstrated in a range of cancers by a few studies and was a prognostic factor in a subset of patients.
OBJECTIVE: The aim of this study was to investigate the relationship of Girdin expression to clinicopathologic factors in terms of the progression of colorectal cancers and patient survival.
DESIGN: This study is a retrospective review of immunohistochemical and clinicopathologic data.
SETTING: This study was conducted at a tertiary care hospital/referral center in South Korea. PATIENTS: Tissue microarrays were made from surgical biopsies of 298 patients with colorectal cancer diagnosed between November 1996 and August 2007. Patients were included in the study if their survival time was known and if well-preserved surgical biopsy specimens were available. MAIN OUTCOME MEASURES: The primary outcomes measured were Girdin expression and its association in tumor progression and patient survival.
RESULTS: Positive staining for Girdin was observed in samples from 66 of 242 patients (27.3%). Expression of Girdin was significantly associated with tumor-node-metastasis stage (p = 0.036), liver metastasis (p = 0.025), and metastases involving the liver and other organs (p = 0.009). However, Girdin expression did not correlate significantly with the overall survival of patients and was not a significant negative prognostic factor for survival by univariate or multivariate analyses. LIMITATIONS: The number of investigated patients and the number of cases with positive staining for Girdin were rather small for the multivariate analysis. The inclusion time frame is long and includes other surgical and medical improvements, which influence a patient's survival.
CONCLUSION: The expression of Girdin is related to tumor metastasis but not to survival in human colorectal cancers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23222280     DOI: 10.1097/DCR.0b013e31826b9b7e

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  14 in total

1.  Membrane Recruitment of the Non-receptor Protein GIV/Girdin (Gα-interacting, Vesicle-associated Protein/Girdin) Is Sufficient for Activating Heterotrimeric G Protein Signaling.

Authors:  Kshitij Parag-Sharma; Anthony Leyme; Vincent DiGiacomo; Arthur Marivin; Stefan Broselid; Mikel Garcia-Marcos
Journal:  J Biol Chem       Date:  2016-11-18       Impact factor: 5.157

Review 2.  GIV/Girdin transmits signals from multiple receptors by triggering trimeric G protein activation.

Authors:  Mikel Garcia-Marcos; Pradipta Ghosh; Marilyn G Farquhar
Journal:  J Biol Chem       Date:  2015-01-20       Impact factor: 5.157

3.  Expression and clinical significance of girdin in gastric cancer.

Authors:  Caihua Wang; Jie Lin; Lurong Li; Yun Wang
Journal:  Mol Clin Oncol       Date:  2014-02-24

4.  GIV/Girdin promotes cell survival during endoplasmic reticulum stress.

Authors:  Peter Nguyen; Rosanna Calderon; Yoanna Rodriguez-Ledezma; Kelly Araujo; Deepali Bhandari
Journal:  Mol Cell Biochem       Date:  2018-08-25       Impact factor: 3.396

5.  Prognostic impact of total and tyrosine phosphorylated GIV/Girdin in breast cancers.

Authors:  Ying Dunkel; Kexin Diao; Nicolas Aznar; Lee Swanson; Lawrence Liu; Wenhong Zhu; Xiao-Yi Mi; Pradipta Ghosh
Journal:  FASEB J       Date:  2016-07-20       Impact factor: 5.191

6.  Inhibition of Girdin enhances chemosensitivity of colorectal cancer cells to oxaliplatin.

Authors:  Ya-Jie Zhang; A-Jian Li; Yi Han; Lu Yin; Mou-Bin Lin
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

7.  Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer.

Authors:  Pradipta Ghosh; Jeanne Tie; Andrea Muranyi; Shalini Singh; Patrick Brunhoeber; Katherine Leith; Rebecca Bowermaster; Zhiming Liao; Yifei Zhu; Bonnie LaFleur; Ben Tran; Jayesh Desai; Ian Jones; Matthew Croxford; Rodrigo Jover; Ajay Goel; Paul Waring; Song Hu; Volker Teichgraber; Ulrich-Peter Rohr; Ruediger Ridder; Kandavel Shanmugam; Peter Gibbs
Journal:  Clin Cancer Res       Date:  2016-03-30       Impact factor: 12.531

8.  Clinical significance of Girdin expression detected by immunohistochemistry in non-small cell lung cancer.

Authors:  Jing-Ying Song; Ping Jiang; Ning Li; Feng-Hua Wang; Jun Luo
Journal:  Oncol Lett       Date:  2013-12-09       Impact factor: 2.967

9.  The Gαi-GIV binding interface is a druggable protein-protein interaction.

Authors:  Vincent DiGiacomo; Alain Ibáñez de Opakua; Maria P Papakonstantinou; Lien T Nguyen; Nekane Merino; Juan B Blanco-Canosa; Francisco J Blanco; Mikel Garcia-Marcos
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

Review 10.  Heterotrimeric G proteins as emerging targets for network based therapy in cancer: End of a long futile campaign striking heads of a Hydra.

Authors:  Pradipta Ghosh
Journal:  Aging (Albany NY)       Date:  2015-07       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.